Irbesartan, amlodipine, or placebo for risk for a composite outcome in diabetic nephropathy and hypertension at mean 2.6 years†
| Comparisons | Event rates | Adjusted RRR (95% CI) | NNT (CI) |
|---|---|---|---|
| †Composite outcome = doubling of baseline serum creatinine level, end stage renal disease, or all cause mortality. Abbreviations defined in glossary; RRR, RRI, and CI adjusted for mean arterial blood pressure; NNT, NNH, and CI calculated from data in article. | |||
| Irbesartan v amlodipine | 33% v 41% | 24% (8 to 37) | 12 (7 to 35) |
| Irbesartan v placebo | 33% v 39% | 19% (1 to 33) | 16 (8 to 121) |
| Adjusted RRI (CI) | NNH | ||
| Amlodipine v placebo | 41% v 39% | 7% (–11 to 29) | Not significant |